Moderna Inc. (NASDAQ:MRNA) shares, rose in value on Wednesday, 06/22/22, with the stock price up by 4.68% to the previous day’s close as strong demand from buyers drove the stock to $136.07.
Actively observing the price movement in the last trading, the stock closed the session at $129.99, falling within a range of $126.59 and $139.90. The value of beta (5-year monthly) was 1.54 whereas the PE ratio was 4.00 over 12-month period. Referring to stock’s 52-week performance, its high was $497.49, and the low was $115.61. On the whole, MRNA has fluctuated by -0.13% over the past month.
With the market capitalization of Moderna Inc. currently standing at about $51.19 billion, investors are eagerly awaiting this quarter’s results, scheduled for Feb 23, 2022 – Feb 28, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be $4.74, which is expected to increase to $13.09 for fiscal year $27.75 and then to about $8.67 by fiscal year 2023. Data indicates that the EPS growth is expected to be -1.90% in 2023, while the next year’s EPS growth is forecast to be -68.80%.
Analysts have estimated the company’s revenue for the quarter at $4.23 billion, with a low estimate of $2.54 billion and a high estimate of $5.04 billion. According to the average forecast, sales growth in current quarter could jump down -2.90%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2023, the company’s y-o-y revenues would reach $21.99 billion, representing an increase of 19.10% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were 3 upward and no downward review(s) in last seven days. We see that MRNA’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of MRNA currently trading nearly 1.11% and -3.37% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 50.76, while the 7-day volatility ratio is showing 6.96% which for the 30-day chart, stands at 6.74%. Furthermore, Moderna Inc. (MRNA)’s beta value is 1.74, and its average true range (ATR) is 9.64.
A comparison of Moderna Inc. (MRNA) with its peers suggests the former has fared considerably weaker in the market. MRNA showed an intraday change of 4.68% in last session, and over the past year, it shrunk by -38.53%%. In comparison, Johnson & Johnson (JNJ) has moved higher at 1.58% on the day and was up 7.41% over the past 12 months. On the other hand, the price of Pfizer Inc. (PFE) has risen 2.00% on the day. The stock, however, is off 23.88% from where it was a year ago. The PE ratio stands at 4.00 for Moderna Inc., compared to 23.67 for Johnson & Johnson, and 11.06 for Pfizer Inc. Other than that, the overall performance of the S&P 500 during the last trading session shows that it lost -0.13%. Meanwhile, the Dow Jones Industrial Slipped by -0.15%.
Data on historical trading for Moderna Inc. (NASDAQ:MRNA) indicates that the trading volumes over the past 10 days have averaged 6.01 million and over the past 3 months, they’ve averaged 6.18 million. According to company’s latest data on outstanding shares, there are 402.00 million shares outstanding.
Nearly 5.30% of Moderna Inc.’s shares belong to company insiders and institutional investors own 64.20% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 15.43 million shares as on Apr 28, 2022, resulting in a short ratio of 2.74. According to the data, the short interest in Moderna Inc. (MRNA) stood at 3.88% of shares outstanding as of Apr 28, 2022; the number of short shares registered in Mar 30, 2022 reached 16.21 million. The stock has fallen by -46.42% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the MRNA stock heading into the next quarter.